Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
48.00    3.50 (7.87%)
Bid:
47.50
Ask:
48.50
Spread: 1.00 (2.105%)
Market Cap: £92.09m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Market Update - Strong H2 2019

16 Jan 2020 07:00

RNS Number : 9501Z
Iofina PLC
16 January 2020
 

 

16 January 2020

 

Iofina plc

("Iofina", the "Group", or the "Company")

(LSE AIM: IOF)

 

 Market Update

 

Strong H2 2019 culminates in record year of iodine production

 

Iodine spot prices up 20% YoY

 

Iofina plc, specialists in the exploration and production of iodine and manufacturers of specialty chemical products, is pleased to update the market on an exceptional year for the Group, in which it produced a record volume of crystalline iodine and continued to execute on the Group's commitment to growth and increased profitability.

 

2019 Performance

Iofina Resources:

·; A record year of crystalline iodine production

o Full year 2019 production totalled 602.7 metric tonnes ("MT") of crystalline iodine (FY 2018: 588.8MT)

o Produced 316MT of crystalline iodine in H2 2019, in-line with the 305-325MT half year expectation

·; Commenced construction of new plant IO#8, currently on time and within budget

·; H1 2020 production currently forecast at 315-345MT of crystalline iodine

·; Continuing exploration program and progressing determination of the next plant site for expansion of iodine production

·; Iodine spot prices rose over 20% in 2019 to $32 - $37/kg

 

Iofina Chemical:

·; Record sales of crystalline iodine, mostly spot (to established, preferred customers), some contracted

·; Price increases for iodine derivative products lagged somewhat behind those for spot sales

·; Non-iodine product sales were strong

·; Plant improvements underway to improve process efficiency and maximise production output

·; Successful hiring of key personnel in 2019 including Production, Engineering and Quality Managers

 

IofinaEX:

·; Hemp has been purchased for development

·; Successfully isolated first CBD oil product from hemp and continuing development work

·; Strategic investment into Organic Vines OP, LLC, a hemp seed growing operation in Colorado

·; Working to develop CBD/hemp opportunities in Belize and Central America

 

During 2019, Iofina achieved a record set of production results, with the Group producing 602.7MT of crystalline iodine (2018: 588.8MT), a 2.3% increase on last year's production output. As a result of the increase in output, combined with rising iodine prices and strong sales from Iofina Chemical's non-iodine products, 2019 was a strong year for the Group.

 

The construction of IO#8 continues to progress well and the new plant is expected to be brought online in April/May 2020. Concrete work has been completed and the electrical and plumbing work is ongoing, whilst the building and mezzanines are simultaneously being installed. In mid-February the Group expects to install extraction towers and other large systems. Once in production, IO#8 will contribute fully to the Group's H2 2020 production output and will have a similar cost per kilo to Iofina's current lowest per kilo production cost plants.

  

Looking ahead to 2020, the Company expects that iodine production will continue to grow. The Group expects to produce between 315-345 MT of crystalline iodine in H1 2020, with levels increasing even further in H2 2020 due to better weather conditions and the addition of IO#8 increasing the Group's overall production.

 

Iodine prices rose over 20% in 2019 and, moving into January 2020, the spot price was generally in the mid $30's/kg, as a result of the continuing demand for iodine and a tightness in supply. The Board believes that contract and spot iodine prices will continue to increase in 2020, coinciding with the Group's expansion with the addition of new iodine plants.

 

Iofina Chemical, the Group's iodine derivative manufacturer located in Covington, KY USA, continues to sell all of the Group's products including crystalline iodine produced by Iofina Resources. In the period under review, and since the Company's placing in June 2019, the Group has been able to allocate the necessary capital to Iofina Chemical to improve efficiencies at the plant in order to meet growing demands for products. Capital spent included improving equipment for certain key iodine derivative products. Additionally, due to increased demand, some operations have increased to a 24/7 work schedule.

 

The Group remains confident in the potential of IofinaEX, the new business entity which is exploring the isolation of specialty chemical products from hemp, a rapidly expanding market. IofinaEx purchased hemp for development in Q3 2019 and has successfully been able to isolate its first CBD oil product from hemp. The Group will continue to develop its strategy in the CBD/Hemp space and looks forward to providing an update on the business plan for these operations, both in the USA and globally in countries such as Belize.

 

Commenting, President and CEO of Iofina, Dr. Tom Becker, stated: "I am delighted to report the Group's exceptional performance in 2019, in which we achieved record iodine production whilst also executing on our expansion at the right time, when iodine prices are continuing to build momentum. With the forthcoming addition of IO#8 we continue to look ahead, and will seek to expand our production capabilities beyond IO#8 this year.

 

"Meanwhile, we are working diligently on debt restructure solutions and are confident we will have a firm plan in place by the time we release our full year results in Q2 2020."

 

Enquiries:

 

Dr. Tom Becker

CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Christopher Raggett/Giles Rolls/Matthew Radley (corporate finance)

Camille Gochez (ECM)

finnCap Ltd

Tel: +44 (0)20 7220 0500

 

Media Contact:

Charles Goodwin/Harriet Jackson

Yellow Jersey PR Limited

Tel: +44 (0)20 3004 9512

About Iofina:

Iofina plc (AIM: IOF) is a vertically integrated Company that specialises in the production of Iodine and the manufacturing of specialty chemical products. As the second largest producer of iodine in North America, it comprises three USA entities; Iofina Resources, Iofina Chemical and IofinaEX.

 

LEI: 213800QDMFYVRJYYTQ84

ISIN: GB00B2QL5C79

 

Iofina Resources

Iofina Resources develops, builds, owns and operates iodine extraction plants using Iofina's WET® IOsorb® technology. Iofina currently operates four producing IOsorb® plants in Oklahoma is building a fifth site, and is consistently using technology and innovation to improve and expand its operations.

 

Iofina Chemical

Iofina Chemical has manufactured high quality halogen speciality chemicals derived from raw iodine, as well as non-iodine based products for over 35 years.

 

IofinaEX

Iofina's newest subsidiary, IofinaEX, is fully licensed to process hemp in the state of Kentucky and is exploring the isolation of specialty chemical products from hemp, a rapidly expanding market.

IofinaEX Global

IofinaEX Global is a Belize based subsidiary company of Iofina exploring CBD/Hemp opportunities in Central America and Caribbean countries.

 

www.iofina.com

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDUVSBRRBUAAAR
Date   Source Headline
14th Jun 20237:00 amRNSIO#9 Iodine Plant Operating
9th May 20237:00 amRNSNotice of AGM
4th May 20237:00 amRNSInvestor Presentation
28th Apr 20234:45 pmRNSHolding(s) in Company
28th Apr 20237:00 amRNSGrant of Share Options
25th Apr 20237:00 amRNS2022 FULL YEAR RESULTS
12th Apr 20237:00 amRNSProduction Update
20th Feb 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSMarket Update
28th Dec 20222:34 pmRNSHolding(s) in Company
14th Dec 20227:00 amRNSIofina Chemical Awarded ISO Certification
21st Nov 20227:00 amRNSChange of Adviser
28th Oct 20227:00 amRNSFinalised Terms for IO9 & Q3 Production Update
26th Sep 202211:06 amRNSSecond Price Monitoring Extn
26th Sep 202211:00 amRNSPrice Monitoring Extension
26th Sep 20227:00 amRNSInterim Results
8th Jul 20227:00 amRNSAdditional Loan Facilities and H1 Update
5th Jul 20228:54 amRNSHolding(s) in Company
22nd Jun 20222:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSAppointment of Chrystal Capital Partners LLP
27th May 20227:00 amRNSNotice of AGM
26th May 20224:15 pmRNSHolding(s) in Company
26th May 20222:15 pmRNSHolding(s) in Company
24th May 20226:15 pmRNSHolding(s) in Company
20th May 20227:10 amRNSInvestor Presentation
18th May 20227:00 amRNSHolding(s) in Company
9th May 20227:00 amRNSFinal Results
5th May 20227:00 amRNSHolding(s) in Company
28th Apr 20228:38 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSQ1 2022 and IO#9 Update
8th Apr 20221:07 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSDirector/PDMR Shareholding
16th Mar 20227:00 amRNSHolding(s) in Company
14th Mar 20227:00 amRNSDirector/PDMR Shareholding
11th Mar 20227:00 amRNSDirector/PDMR Shareholding
10th Mar 20227:00 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSGrant of Share Options
8th Mar 20228:51 amRNSHolding(s) in Company
17th Jan 20229:00 amRNSPrice Monitoring Extension
17th Jan 20227:00 amRNSQ4 2021 Update
10th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20227:00 amRNSHolding(s) in Company
29th Dec 20217:00 amRNSBusiness Update
20th Oct 202112:44 pmRNSHolding(s) in Company
15th Oct 20217:00 amRNSQ3 2021 Update
12th Oct 20218:47 amRNSHolding(s) in Company
24th Sep 20217:00 amRNSInterim Results
23rd Sep 20214:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.